MiNK Therapeutics, Inc. (INKT)
INKT Stock Price Chart
Explore MiNK Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze INKT price movements and trends.
INKT Company Profile
Discover essential business fundamentals and corporate details for MiNK Therapeutics, Inc. (INKT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Oct 2021
Employees
23.00
Website
https://minktherapeutics.comCEO
Jennifer S. Buell
Description
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Financial Timeline
Browse a chronological timeline of MiNK Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.60.
Earnings released on 15 May 2026
EPS came in at -$0.57 surpassing the estimated -$0.77 by +25.97%.
Earnings released on 17 Mar 2026
EPS came in at -$0.52 surpassing the estimated -$0.68 by +23.53%.
Earnings released on 14 Nov 2025
EPS came in at -$0.65 surpassing the estimated -$0.86 by +24.42%.
Earnings released on 14 Aug 2025
EPS came in at -$1.06 falling short of the estimated -$0.55 by -92.73%.
Earnings released on 15 May 2025
EPS came in at -$0.70 falling short of the estimated -$0.61 by -14.75%.
Earnings released on 18 Mar 2025
EPS came in at -$0.62 falling short of the estimated -$0.50 by -24.00%.
Stock split effective on 28 Jan 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$0.50 surpassing the estimated -$0.80 by +37.50%.
Earnings released on 13 Aug 2024
EPS came in at -$0.70 surpassing the estimated -$1.00 by +30.00%.
Earnings released on 14 May 2024
EPS came in at -$1.10 surpassing the estimated -$1.60 by +31.25%.
Earnings released on 21 Mar 2024
EPS came in at -$1.60 falling short of the estimated -$1.50 by -6.67%, while revenue for the quarter reached -$11.71bn .
Earnings released on 9 Nov 2023
EPS came in at -$1.50 surpassing the estimated -$1.80 by +16.67%.
Earnings released on 10 Aug 2023
EPS came in at -$1.80 surpassing the estimated -$1.90 by +5.26%.
Earnings released on 11 May 2023
EPS came in at -$1.70 surpassing the estimated -$2.40 by +29.17%, while revenue for the quarter reached $11.71bn .
Earnings released on 21 Mar 2023
EPS came in at -$2.30 falling short of the estimated -$2.10 by -9.52%, while revenue for the quarter reached $2.70bn .
Earnings released on 3 Nov 2022
EPS came in at -$1.90 surpassing the estimated -$2.30 by +17.39%, while revenue for the quarter reached $1.56bn .
Earnings released on 9 Aug 2022
EPS came in at -$1.80 surpassing the estimated -$2.40 by +25.00%, while revenue for the quarter reached $1.56bn .
Earnings released on 10 May 2022
EPS came in at -$2.30 falling short of the estimated -$2.10 by -9.52%.
Earnings released on 18 Mar 2022
EPS came in at -$1.80 surpassing the estimated -$2.40 by +25.00%, while revenue for the quarter reached $221.92m .
Earnings released on 29 Nov 2021
EPS came in at -$0.59 falling short of the estimated -$0.20 by -195.00%.
Earnings released on 15 Oct 2021
EPS came in at -$0.22 .
INKT Stock Performance
Access detailed INKT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
